Introduction
Sepsis remains a formidable challenge in critical care medicine, characterized by life-threatening organ dysfunction caused by a dysregulated host response to infection. Among the various complications, sepsis-induced cardiomyopathy (SICM) stands out as a major contributor to mortality. Despite its clinical significance, the management of SICM remains largely supportive, primarily because the underlying molecular and cellular dynamics are not fully understood. Traditional research has often viewed the heart as a homogenous muscular pump, but recent advancements in single-cell technologies are revealing a more complex landscape of cellular heterogeneity.
The Challenge of Sepsis-Induced Cardiomyopathy
SICM is characterized by acute ventricular dysfunction, including both systolic and diastolic impairment, which is often reversible if the patient survives the initial inflammatory storm. However, the presence of SICM significantly increases the risk of death. Historically, the mechanisms cited include mitochondrial dysfunction, oxidative stress, and impaired calcium handling. Yet, therapies targeting these pathways have seen limited success in clinical trials. A key limitation has been the lack of high-resolution data on how individual cardiomyocytes respond to the systemic inflammatory environment of sepsis.
Study Design and Methodology
In a landmark study published in the European Heart Journal (2025), Yang et al. addressed this knowledge gap using single-nucleus RNA sequencing (snRNA-seq) to map the transcriptomic dynamics of the heart at the single-cell level. The researchers utilized a caecal ligation and puncture (CLP) mouse model to simulate human sepsis. Their investigation spanned various models, including:
Experimental Models
1. In vitro: Cultured neonatal rat ventricular myocytes, human embryonic stem cell-derived cardiomyocytes, and adult rat and human ventricular myocytes.
2. In vivo: CLP-induced sepsis and lipopolysaccharide (LPS)-induced myocardial injury models in mice.
3. Human Validation: Analysis of human heart tissue to confirm the relevance of findings in clinical settings.
Key Findings: The Discovery of Cardiomyocyte Subtypes
The snRNA-seq analysis revealed that cardiomyocytes are not a monolith. In healthy hearts, cardiomyocytes are primarily categorized into three distinct subtypes:
1. Contractile Cardiomyocytes: The predominant type, responsible for the mechanical work of the heart.
2. Injury-Responsive Cardiomyocytes: A specialized subtype that emerges or expands during stress.
3. Transitional Cardiomyocytes: Cells in an intermediate state between the two.
The Phenotypic Switch
During the early stages of sepsis, the study observed a dramatic conversion where contractile cardiomyocytes shifted into the injury-responsive subtype. While this conversion led to a measurable reduction in myocardial contractility and overall heart function, it appeared to serve a protective role. By shifting into this injury-responsive state, the cells were able to suppress the production of reactive oxygen species (ROS) and mitigate acute cellular damage. This suggests that the initial cardiac depression in sepsis might be an adaptive, albeit clinically dangerous, survival mechanism—reminiscent of “myocardial hibernation.”
The Role of ERRγ as a Molecular Switch
Through detailed transcriptomic mapping, the researchers identified oestrogen-related receptor γ (ERRγ) as the central regulator of this subtype conversion. ERRγ is a nuclear receptor known for its role in regulating oxidative metabolism and mitochondrial function in high-energy tissues like the heart.
The study found that sepsis leads to a significant reduction in ERRγ expression within contractile cardiomyocytes. This loss of ERRγ is what triggers the transition into the injury-responsive phenotype. Conversely, maintaining or restoring ERRγ levels prevented this shift, although the timing of such intervention is critical.
Therapeutic Potential of ERRγ Agonists
One of the most promising aspects of this research is the therapeutic application of ERRγ agonists. In the CLP mouse model, the administration of an ERRγ agonist after the acute phase of infection promoted the “back-conversion” of injury-responsive cardiomyocytes into the contractile subtype. This transition resulted in:
– Improved cardiac contractility.
– Restored ventricular function.
– Enhanced overall prognosis and survival rates.
This finding is particularly relevant for the recovery phase of sepsis, where patients often struggle with persistent cardiac weakness despite the resolution of the primary infection.
Clinical Implications and Human Validation
The researchers successfully validated these findings in human heart samples, confirming that sepsis-elicited cardiomyocyte subtype conversion is a conserved biological process. This bridges the gap between murine models and clinical reality, suggesting that ERRγ-targeted therapies could be a viable strategy for human SICM.
Expert Commentary and Mechanistic Insights
The study by Yang et al. provides a sophisticated look at the “double-edged sword” nature of the cardiomyocyte response to sepsis. The transition to an injury-responsive state is likely an evolutionarily conserved mechanism to protect the cell’s structural integrity at the cost of its functional output. However, in the context of modern intensive care, where we can support other organs, the persistent loss of contractile function becomes the primary threat.
Biological Plausibility
The involvement of ERRγ is biologically plausible given the metabolic shifts seen in the septic heart. Sepsis is known to induce a “metabolic coma” in mitochondria. Since ERRγ is a master regulator of the nuclear-encoded mitochondrial gene program, its downregulation explains the metabolic shutdown observed in SICM. By using agonists to re-engage this receptor, we are essentially “re-starting” the metabolic engine of the cardiomyocyte once the inflammatory threat has subsided.
Conclusion
This research represents a paradigm shift in our understanding of sepsis-induced cardiomyopathy. By identifying ERRγ as the gatekeeper of cardiomyocyte identity, it moves the field beyond general descriptions of “inflammation” toward specific, druggable cellular transitions. Activating ERRγ offers a dual benefit: it respects the protective nature of the initial cellular response while providing a clear pathway to restore functional capacity during recovery. Future clinical trials will be necessary to determine the optimal window for ERRγ agonist administration in septic patients, potentially ushering in a new era of precision cardiology in the ICU.
References
1. Yang J, Wang Z, Lyu Y, et al. Oestrogen-related receptor γ in sepsis-induced cardiomyopathy: role of cardiomyocyte subtype conversion. Eur Heart J. 2025; doi:10.1093/eurheartj/ehaf980.
2. Al-Khafaji A, et al. Sepsis-induced myocardial dysfunction: from pathogenesis to treatment. Nat Rev Cardiol. 2020.
3. Giguère V. Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev. 2008.